FDA Warns Public Over Falsified Dr Alfred Capsules Adulterated With Sildenafil Citrate
The Food and Drugs Authority (FDA) has warned the public about the circulation of falsified Dr. Alfred Capsules, a dietary supplement for male vitality, on various social media platforms.
In a public release dated September 09, 2026, the Authority said the capsules in question have not been registered by the FDA and pose a critical public health risk.
According to the FDA, following regulatory intelligence and subsequent enforcement operations, it has identified an organised syndicate operating in Accra and Suhum that manufactures and distributes the falsified products across the country.
The Authority said two suspects linked to the illicit activity are currently on police enquiry bail, assisting with ongoing investigations, adding that the falsified capsules are produced in unauthorised, unregulated and unhygienic environments.
The FDA said laboratory analysis by its Centre for Laboratory Services and Research (CLSR) confirmed that the falsified variants have been adulterated with Sildenafil Citrate, an allopathic drug substance.
Sildenafil Citrate, it explained, is a Phosphodiesterase Type 5 (PDE5) inhibitor and an undeclared drug substance in the falsified product. It is a prescription-only medicine used to treat erectile dysfunction in men, as well as pulmonary arterial hypertension.
The Authority clarified that the registered product is manufactured by CV Al Manar Herbafit, Jl. Imogiri, Bantul, DI Yogyakarta 55194, Indonesia, and registered by Unateus Ghana Limited as a food supplement. The registered product does not contain Sildenafil Citrate.
The FDA outlined differences between the registered and falsified products.
It said the registered product has high-quality container material, distinctive text alignment and secure, premium exterior finishes in a pack size of 30 capsules only, while the falsified version is of low quality, with inferior print resolution and blurred or altered typography in varying pack sizes of 30 or 60 capsules.
It added that the registered product has clear, traceable batch numbers matching on both the label and at the base of the container, while the falsified product has no matching batch numbers and bears fictitious FDA registration numbers on the labels.
On security sealing, the registered product features uniform, intact tamper-evident sealing characteristics unique to the Marketing Authorisation Holder on the bottle cap, with an aluminium inner seal on first opening, whereas the falsified products have missing safety seals and may or may not have an aluminium inner seal.
The FDA further noted that the registered product has standardised wine-red capsule shell colouration containing uniform off-white fine powder, while the falsified products show stark differences in capsule shell colours, including transparent or black and red shells, containing greenish-brown powder.
Click to read more: https://opemsuo.com/author/hajara-fuseini/
